

Vanguard DA2PI-CPV Lyofilisaat en oplosmiddel voor suspensie voor injectie

Authorised

- Canine parainfluenza virus, strain NL-CPI-5, Live
- Canine adenovirus 2, strain Manhattan, Live
- Canine parvovirus, strain NL-35-D, Live
- Canine distemper virus, strain N-CDV, Live

Product identification

Medicine name:

Vanguard DA2PI-CPV Lyofilisaat en oplosmiddel voor suspensie voor injectie

Active substance:

Canine parainfluenza virus, strain NL-CPI-5, Live

Canine adenovirus 2, strain Manhattan, Live

Canine parvovirus, strain NL-35-D, Live

Canine distemper virus, strain N-CDV, Live

Target species:

Dog

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Canine parainfluenza virus, strain NL-CPI-5, Live
6.00 log₁₀ 50% cell culture infectious dose / 1.00 millilitre(s)

Canine adenovirus 2, strain Manhattan, Live
3.20 log₁₀ 50% cell culture infectious dose / 1.00 millilitre(s)

Canine parvovirus, strain NL-35-D, Live
7.00 log₁₀ 50% cell culture infectious dose / 1.00 millilitre(s)

Canine distemper virus, strain N-CDV, Live
3.00 log₁₀ 50% cell culture infectious dose / 1.00 millilitre(s)

Pharmaceutical form:

Lyophilisate and solvent for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AD04

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Belgium

Available in:

Belgium

Package description:

Vanguard DA2PI-CPV 25 Vials with Lyophilisate and 25 Vials with solvent for suspension for injection

Vanguard DA2PI-CPV 100 Vials with Lyophilisate and 100 Vials with solvent for suspension for injection

Vanguard DA2PI-CPV 10 Vials with Lyophilisate and 10 Vials with solvent for suspension for injection

Vanguard DA2PI-CPV 1 Vial with Lyophilisate and 1 Vial with solvent for suspension for injection

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Zoetis Belgium

Marketing authorisation date:

30/03/1993

Manufacturing sites for batch release:

Zoetis Belgium

Responsible authority:

Federal Agency For Medicines And Health Products

Authorisation number:

BE-V161506

Date of authorisation status change:

1/03/2017

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.